Articles

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Faculty of Medicine, University of Southampton, Southampton, UK;Wessex Regional Genetics Laboratory, Salisbury, UK
Faculty of Medicine, University of Southampton, Southampton, UK;Wessex Regional Genetics Laboratory, Salisbury, UK
Faculty of Medicine, University of Southampton, Southampton, UK;Wessex Regional Genetics Laboratory, Salisbury, UK
Münchner Leukämie Labor, München, Germany
Münchner Leukämie Labor, München, Germany
III Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
III Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
III Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
Faculty of Medicine, University of Southampton, Southampton, UK;Wessex Regional Genetics Laboratory, Salisbury, UK
Vol. 98 No. 3 (2013): March, 2013 https://doi.org/10.3324/haematol.2012.067959